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Abstract
Introduction: We aimed to investigate the sensitivity and reliability of two-dimensional ultrasonographic endpoints
at the metacarpophalageal joints (MCPJs) and their potential to provide an early and objective indication of a
therapeutic response to treatment intervention in rheumatoid arthritis (RA).
Methods: A randomized, double-blind, parallel-group, two-center, placebo-controlled trial investigated the effect
on ultrasonographic measures of synovitis of repeat dose oral prednisone, 15mg or 7.5mg, each compared to
placebo, in consecutive two-week studies; there were 18 subjects in a 1:1 ratio and 27 subjects in a 2:1 ratio,
respectively. All subjects met the 1987 American College of Rheumatology criteria for the diagnosis of RA, were
≥18 years-old with RA disease duration ≥6 months, and had a Disease Activity Score 28 based on C-reactive
protein (DAS28(CRP)) ≥3.2. Subjects underwent high-frequency (gray-scale) and power Doppler ultrasonography at
Days 1 (baseline), 2, 8 and 15 in the dorsal transverse and longitudinal planes of all 10 MCPJs to obtain summated
scores of quantitative and semi-quantitative measures of synovial thickness as well as vascularity. The primary
endpoint was the summated score of power Doppler area measured quantitatively in all 10 MCPJs in the
transverse plane at Day 15. Clinical efficacy was assessed at the same time points by DAS28(CRP).
Results: All randomized subjects completed the trial. The comparison between daily 15 mg prednisone and
placebo at Day 15 yielded a statistically significant treatment effect (effect size = 1.17, P = 0.013) in change from
baseline in the primary endpoint, but borderline for prednisone 7.5 mg daily versus placebo (effect size = 0.61, P =
0.071). A significant treatment effect for DAS28(CRP) was only observed at Day 15 in the prednisone 15 mg group
(effect size = 0.95, P = 0.032). However, significant treatment effects at all time points for a variety of ultrasound
(US) endpoints were detected with both prednisone doses; the largest observed effect size = 2.33. Combining US
endpoints with DAS28(CRP) improved the registration of significant treatment effects. The parallel scan inter-reader
reliability of summated 10 MCPJ scores were good to excellent (ICC values >0.61) for the majority of US measures.
Conclusions: Ultrasonography of MCPJs is an early, reliable indicator of therapeutic response in RA with potential
to reduce patient numbers and length of trials designed to give preliminary indications of efficacy.
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Introduction
The development of new therapeutics for rheumatoid
arthritis (RA) involves clinical assessment of response by
endpoints that include composite measures of disease
activity, such as the Disease Activity Score in 28 Joints
(DAS28) [1], a continuous measure, and American College
of Rheumatology (ACR) categorical responses [2,3]. Many
of the component measurements are subjective, imprecise
and insensitive to change and their use often necessitates
lengthy and costly clinical trials using large cohorts of
patients. This results in greater exposure to experimental
drugs in early testing, many of which will eventually fail to
receive approval.
For early testing of novel therapeutics, we require a
sensitive method to distinguish between treatment
groups in cohort studies that permits small patient num-
bers and provides a reliable, early indicator of efficacy.
Ideally, such measures would be quick, non-invasive,
objective, predict longer-term response to repeated medi-
cation and give an early indication of disease modifica-
tion. Due to ethical constraints of performing placebo
controlled trials and the resultant trend towards com-
parator controlled trials, the requirement for sensitive
endpoints is greater than ever.
Metacarpophalangeal joints (MCPJs) are invariably
involved in RA [4] and so their evaluation is important.
These superficial joints are amenable to assessment with
ultrasound (US) utilizing frequencies that produce high
resolution images. High-frequency ultrasonography
(HFUS) and power Doppler ultrasonography (PDUS) are
reproducible tools for determining synovitis and more
sensitive than clinical scoring in determining disease activ-
ity [5,6]. The synovial vascular signal on PDUS closely cor-
relates with the dynamic contrast enhanced magnetic
resonance imaging (MRI) in RA MCPJs [7,8] and synovitis
detected by US predicts erosive disease [9-12].
By using a known efficacious treatment for RA, our
objectives were:
1. To investigate the sensitivity and reliability of two-
dimensional ultrasonographic endpoints (quantitative
and semi-quantitative measures of synovial thickness
and vascularity in MCPJs imaged in the dorsal longitudi-
nal and transverse planes) and make comparisons
between different endpoints. We have investigated the
reliability of a summation of 10 MCPJs rather than the
reliability on a joint by joint basis.
2. To determine the potential of two-dimensional
ultrasonographic endpoints to provide an early and
objective indication of a therapeutic response to treat-
ment intervention in rheumatoid arthritis (RA).
3. To determine if there is a dose-response relation-
ship between the two different relatively low, corticos-
teroid doses (15 mg and 7.5 mg) and ultrasonographic
endpoints.
4. To compare the US endpoints with DAS28(CRP)
(C-reactive protein) and to explore the potential of com-
posite endpoints (DAS28 combined with US endpoints)




Protocol 088 (clinicaltrials.gov identifier: NCT00746512)
was a randomized, double-blind, parallel-group, placebo-
controlled trial conducted at two academic research cen-
ters in the UK. Two panels were planned for the study: In
Panel A, subjects were randomized in a 1:1 ratio to oral
prednisone 15 mg daily or matching placebo for 15 days.
After a total of 18 subjects completed the study, an interim
analysis was planned to determine if this smaller sample
size could significantly (alpha = 0.03, 1-sided) discriminate
prednisone 15 mg from placebo based on the primary
endpoint. If so, then enrollment in the prednisone 15 mg
group would cease, and 27 additional subjects would be
randomized (2:1 ratio) in Panel B to prednisone 7.5 mg or
matching placebo for 15 days.
Two centers were chosen for feasibility of recruitment to
the study. One of our general aims is to investigate the
applicability of US endpoints in multi-center clinical trials.
Men and nonpregnant women ≥18 years old with RA
for ≥ six months duration meeting the 1987 American
College of Rheumatology criteria for the diagnosis of RA
were eligible [13]. Subjects were required to have at least
moderate disease activity (DAS28(CRP) ≥3.2) and moder-
ate dorsal transverse synovial vascularity in two MCPJs
(score ≥2) or severe in one MCPJ (score = 4) as measured
on a semi-quantitative 0 to 4 scale.
Non-steroidal anti-inflammatory drugs (NSAIDs) at
stable doses for ≥ four weeks were permitted, as were
disease modifying anti-rheumatic drugs (DMARDs) at
stable doses for ≥ six weeks, topical or inhaled glucocor-
ticoids at stable doses for ≥ two weeks, and opiates at
stable doses ≥ two weeks. Acetaminophen (paracetamol)
was allowed for breakthrough pain, but NSAIDs were
not to be taken on an as-needed basis.
Pertinent exclusion criteria included intra-articular glu-
cocorticoid injections to MCPJs within three months or to
non-MCP Js within six weeks of baseline; oral glucocorti-
coid use within four weeks; and current biological
therapies.
Tolerability was assessed by clinical and laboratory
examination and adverse event (AE) reporting during the
study. After baseline measures subjects were randomized
(by a sponsor statistician using a computerized Clinical
Allocation Schedule System (CASS) with blocking factors
to ensure blinding based on a multiple of the number of
treatment groups and subjects) and then received their
first dose of study medication.
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All subjects gave informed written consent to partici-
pate. The study was conducted in accordance with the
principles of Good Clinical Practice and approved by
the institutional review board for human research.
Ultrasonography
Assessment of reliability has been complicated by a
diversity of nomenclature employed by different investi-
gators. Terms for assessment of reliability are redefined
below to avoid confusion. The ultrasonographer is
usually also a reader of the anonymized images.
Within scan intra-reader: one patient, one ultrasono-
grapher acquires one scan set, one reader reads the scan
set twice; each reading is separated by a fixed time period
(previously called intra-reader [14] and intraobserver
[10,15]).
Within scan inter-reader: one patient, one ultrasono-
grapher acquires one scan set, two independent readers
(previously called inter-reader [14], interobserver
[11,16-18] and inter-investigator [19]).
Parallel scan intra-reader: one patient, one ultrasono-
grapher acquires two scan sets sequentially, one reader
independently reads both scan sets (previously called
intraobserver [20]).
Parallel scan inter-reader: one patient, two ultrasono-
graphers each acquire a scan set independently, two
readers each read their own acquired scan set indepen-
dently (previously called interobserver [15,16,20-26]).
Imaging was performed at two centers (Kennedy Insti-
tute of Rheumatology (KIR) and St Bartholomew’s and
the London National Health Services Trust (B&L)) by
two ultrasonographers (MS and SK, each with more than
two years experience), both blinded to the subjects’
group allocation. They spent approximately 16 hours
together before the study to gain consensus on image
acquisition and analysis. To determine reliability (within
scan inter-reader, parallel scan intra-reader and parallel
scan inter-reader) three scans were sequentially acquired
at Day 1 (baseline) and on Day 15 according to Table 1.
Using a GE Logiq9 ultrasound machine with a two-
dimensional M12L transducer at each center, subjects
underwent HFUS and PDUS scanning over the dorsum
of all 10 MCPJs at Days 1, 2, 8 and 15 in the longitudinal
and transverse (over the triangular structure - method
previously described [27]) planes. Settings were identical
on both GE Logiq9 ultrasound machines: HFUS (gray-
scale) - Frequency 14 MHz; PD - Frequency 7.5 MHz,
Gain 41, PRF 1.4 kHz, Wall Filter 127 Hz. With a view to
standardization of data acquisition, the hands were main-
tained in a position of rest by a splint (identical at both
sites). The time of day of scanning at each visit was
within 1 hour of the time of the baseline visit. Care was
taken when scanning to avoid undue pressure with the
probe in case this altered blood flow in the joint. This
was achieved by maintaining a distance of at least 1 mm
of gel between the probe and the subject as visualized on
the US monitor.
Stored clips and images were anonymized before read-
ing. Each PDUS scan consisted of a three second movie
clip. PDUS measures were made on the image frame at
the peak of the PDUS signal and synovial area measures
were made from the first technically qualified image on
HFUS imaging.
The Synovial Thickness Area (STA), a quantitative
measure, is a count of the number of pixels within a
defined region of interest (ROI) in a standardized two-
dimensional image of the joint. For the longitudinal STA
(Long STA) the ROI should envelop the synovium over
the phalangeal base, triangular structure, metacarpal
head and metacarpal notch to the joint capsule super-
iorly. For the transverse STA (Trans STA) the ROI
should envelop the MCPJ synovium from the lower bor-
der of the triangular structure (if bone, this is indicated
by a continuous hyperechoic line or if cartilage by a
homogenous anechoic line above bone) to the joint cap-
sule superiorly (Figure 1). The transverse and longitudi-
nal STA from each of the 10 MCPJs were summated in
each respective plane to create the 10MCP Trans STA
and 10MCP Long STA.
Synovial thickness (ST) was graded semi-quantitatively
in each MCP joint against a standardized image set on an
ordinal scale ranging from 0 to 4: 0, no synovial thicken-
ing; 1, minimal; 2; mild; 3, moderate; 4, severe (Figure 1).
The longitudinal and the transverse ROIs that were com-
pared with the representative images were the same as
the respective STA ROIs. The saved gray-scale image was
compared with the library and MS and SK decided which
representative image was the closest fit with regard to
area of ST and allocated a score. The scores from each of
Table 1 Scan/Reader Scheme.
Site Scan Ultrasonographer Reader
1 (KIR) 1 1 (MS) 1 (MS)
2 (SK)
2 2 (SK) 2
3 1 1
2 (B&L) 1 2 (SK) 2 (SK)
1 (MS)
2 1 (MS) 1
3 2 2
Within scan inter-reader reproducibility is obtained by comparing scan
1values across the two readers. Parallel scan intra-reader reproducibility is
obtained by comparing scan 1 read by the first reader and scan 3 read by the
first reader. Parallel scan inter-reader reproducibility is obtained by comparing
scan 1 read by the first reader and scan 2 read by the second reader. The
scans acquired and read by the site ultrasonographer-reader (indicated in
italics) were used to calculate treatment effects. KIR: Kennedy Institute of
Rheumatology and B&L: St Bartholomew’s and the London NHS Trust. MS
based at KIR travelled to B&L for the subjects’ Day 1 and Day 15 imaging and
vice versa for SK who was based at B&L.
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the 10 MCPJs were summated to create a Synovial Thick-
ness Index (STi; minimum score of 0 and a maximum of
40) for each plane; the 10MCP Trans STi and 10MCP
Long STi.
The Power Doppler Area (PDA), a quantitative mea-
sure, is a count of the number of pixels with PDUS sig-
nal, uncorrected for pixel intensity, within a defined ROI
in a standardized two-dimensional image of the joint.
The ROIs for longitudinal and transverse PDA are the
same as the corresponding ROI for STA and therefore
extraarticular digital vessels are excluded. If present,
reflection artifacts from digital vessels are also excluded
if they enter the ROI (Figure 1). The transverse and long-
itudinal PDAs from each of the 10 MCPJs were sum-
mated in each respective plane to create the 10MCP
Trans PDA and 10MCP Long PDA.
PDUS was also graded in each MCPJ using a semi-
quantitative 0-to-4 vascularity scale: 0, no PD signal; 1,
Figure 1 Illustration of ultrasonographic scanning in the longitudinal and transverse plane using a splint to standardize image
acquisition. The four columns contain the semi-quantitative scales with scores from 0 to 4: 0 representing the lack of PD signal and 4 being
severe PD signal; 0 representing no synovial thickening and 4 being severe synovial thickening. The last row demonstrates the region of interest
(ROI) for quantitative analysis. Images were cropped for clarity. LONG: longitudinal, TRANS: transverse, ST: synovial thickening, VASC: vascularity,
Quant ROI: region of interest for quantitative analysis, STA: synovial thickness area, PDA: power Doppler area.
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minimal; 2; mild; 3, moderate; 4, severe. As for the PDA
the longitudinal and the transverse ROIs were the same
as the respective STA ROIs. Images were graded against
a library of representative images (Figure 1), that is, for
each selected image MS and SK visually estimated the
amount of colored pixels within the joint capsule, com-
pared this with the library, decided which representative
image was the closest fit and allocated a score. The
scores from each of the 10 MCPJs were summated to
create a Vascularity Index (VASCi: minimum score of 0
and a maximum of 40) for each plane, the 10MCP
Trans VASCi and 10MCP Long VASCi. The 10MCP
Trans PDA was the primary endpoint; the other US
endpoints were secondary. The transverse view was cho-
sen as this had previously demonstrated its utility in dif-
ferentiating two groups in a randomized placebo
controlled trial [12].
Quantitative vascularity and ST measurements were
analyzed using the free downloadable software program
ImageJ version 1.41 with an in-house plugin written by
BD which enabled a rapid review of each PD clip to find
the frame that displayed the most activity.
Several published four point scales for power Doppler
(PD) have no PD signal as the lowest grade (normal), pre-
sence of a single vessel (mild) as the next grade and then
less than 50% (moderate) and greater than 50% (severe)
PD signal to gray-scale signal within the ROI to determine
the next two grades [6,21,26]. The majority of published
four-point gray-scale semi-quantitative scales of synovial
thickening/synovitis are explained simply as subjective
grading with four points (normal, mild, moderate and
severe) [6,21,23]. Those that are described in detail exam-
ine the extent at which synovitis breaches boundaries to
determine the grade of synovitis [19,26]. Ordinal grading
scales typically infer linearity and equidistance between
grading points, whereas the above mentioned four-point
vascularity scales lack grading points at low levels of
Doppler signal, potentially underestimating change (either
up or down) in response to therapy. Our rationale for
increasing the semi-quantitative scales for scoring by one
point was to provide semi-quantitative ultrasonographic
outcome measures that are potentially more sensitive to
change. We developed a five point scale for synovial vascu-
larity. The basis for this is that within the above men-
tioned four-point vascularity scales there is potentially a
leap between mild and moderate. In our experience there
are often images that the four point scales [6,21,26] would
class as moderate which we would still consider as mild,
for example, two vessels and up to three small areas of
confluence. We have made provision for this. On our scale
these two examples would score two and, therefore, one
vessel scores one on our scale, minimal. This additional
grade may serve to improve the sensitivity. Therefore,
another objective of this study was to investigate this five-
point scale for vascularity and also the novel five-point
scale for ST. In support of the library of images approach
to semi-quantitative scoring of synovitis, a recent study
that utilized a US atlas has reported excellent parallel scan
inter-reader reliability (intra-class correlation coefficients
(ICC) values: gray-scale 0.95 and PD 0.97) [28].
Clinical efficacy assessments
Clinical efficacy was assessed by the DAS28(CRP), which
includes the number of swollen and tender joints (28-
joint count), a patient’s global assessment of arthritis
index (visual analogue scale) and CRP. Assessments were
performed by a single rheumatology research nurse in
each center, independent of the US examinations. Each
study nurse attended a DAS28 standardization training
course within the preceding year of the study start.
Statistical analysis
The primary hypothesis for both panels was that predni-
sone (15 mg or 7.5 mg) would have a greater change
from baseline in 10MCP Trans PDA (the primary end-
point) after 15 days of treatment. The analysis was per-
formed using an analysis of covariance model with panel
and treatment nested within panel as factors, and base-
line value included as a covariate. Only observed data
were analyzed; missing data were not imputed. The ana-
lyses were carried out for change from baseline at each of
days 15, 8, and 2. Interpretation of P-value testing for
each endpoint was made in a step-down fashion, in that
order, at a = 0.05 (1-sided) for the primary endpoint. For
Panel A Days 1 and 15, the first scan set acquired and
read by the ultrasonographer-reader associated with the
clinical site was used for analysis of treatment effects and
for correlation with other endpoints; there was one scan
set per visit for all other study time points.
For the interim analysis following Panel A, if the true
underlying effect size for the primary endpoint was 1.0,
the overall power, accounting for the interim and a
potential final analysis if the study continued as originally
planned, was approximately 88% for 18 subjects per
group and approximately 83% for 15 subjects per group.
The probability of stopping at the interim analysis was
approximately 63%. These computations employ the
Hwang, Shih, deCani gamma = 1 stopping criteria which
yields a = 0.03, 1-sided at the interim and, if applicable,
final analyses. This controls the overall alpha level at
0.05, 1-sided. If the study continued after the interim
analysis, a sample size of 15 subjects per group had 80%
power to detect a statistically significant (a = 0.05,
1-tailed) difference between prednisone and placebo
assuming an effect size of 0.93.
Significance for the effect of the secondary imaging
endpoints and DAS28(CRP) was not error-protected
from chance significance associated with multiple com-
parisons. The rationale for this choice is to minimize
the chances of false negatives because of the exploratory
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nature of these secondary endpoint analyses. Thus, they
are viewed as hypothesis generating rather than
conclusive.
The repeated measures on Days 1 and 15 of Panel A
were used to assess reproducibility (Table 1) using
intra-class correlation coefficients for each endpoint.
Pearson correlation coefficients were computed among
pairs of endpoints, including DAS components, with US
endpoints, to assess association among them.
For the analysis of creating a composite PDUS and
DAS28 endpoint, precision was measured by effect size
(average effect of the 15 mg and 7.5 mg prednisone
effects minus placebo divided by pooled standard devia-
tion) using a model with panel and treatment nested
within panel as factors. The method for building compo-
sites was the O’Brien global statistic which is the average
of the standard z-scores across the endpoints.
All tests were performed one-sided at level 0.05.
Results
Patients
Baseline subject and disease characteristics are shown in
Table 2. Due to an error in the randomization code, there
was uneven subject allocation in Panel A. There were no
significant differences between baseline characteristics in
subjects enrolled in Panels A and B or between those in
each treatment assignment within Panel A and B. All
treatments were generally well-tolerated. A total of 19 sub-
jects reported 31 AEs (including 6 AEs with onset at
prestudy/pre-treatment). There was one serious AE of
breast carcinoma which was not considered by the investi-
gator to be drug-related. None of the subjects enrolled dis-
continued due to an AE.
Endpoint responsiveness
The comparison between prednisone 15 mg daily and
placebo at Day 15 in Panel A yielded a statistically sig-
nificant treatment effect (effect size = 1.17, P = 0.013) in
change from baseline in the primary endpoint, 10 MCP
Trans PDA, but not for Panel B (prednisone 7.5 mg
daily versus placebo) (effect size = 0.61, P = 0.071). The
primary endpoint was also met as early as Day 8 in
Panel B with 7.5mg daily prednisone (effect size = 0.98,
P = 0.01) but no statistically significant treatment effect
was detected at Day 2 or at Days 2 and 8 in Panel A,
15mg prednisone daily (Figure 2).
A significant effect of prednisone 15 mg was observed
for the secondary endpoint, DAS28(CRP), only at Day
15 (effect size = 0.95, P = 0.032). Prednisone 7.5 mg did
not show any significant effect for DAS28(CRP) at any
time point.
With respect to the seven secondary US endpoints, in
Panel A there was a general trend for the number of sig-
nificant treatment effects to increase from Day 2 to Day
15 (Figure 2). In Panel B the largest number of significant
treatment effects was observed at Day 8. The US end-
point with the largest observed effect size, 2.33, was the
10MCP Long STA found within Panel B at Day 15.
Table 2 Baseline patient characteristics.










Female 6 (75.0) 5 (50.0) 12 (66.7) 6 (66.7)
Male 2 (25.0) 5 (50.0) 6 (33.3) 3 (33.3)
Age, years
Mean (SD) 61.6 (6.5) 58.4 (12.8) 57.9 (13.3) 55.1 (12.8)
Range 48 to 69 45 to 86 37 to 81 32 to 71
Race, number (%)
Asian 0 (0.0) 3 (30.0) 2 (11.1) 3 (33.3)
Black 0 (0.0) 1 (10.0) 4 (22.1) 0 (0.0)
White 8 (100.0) 6 (60.0) 12 (66.7) 6 (66.7)
10MCP Trans PDA, mean (SD) 9.48 (6.44) 10.55 (9.54) 8.31 (8.66) 9.78 (7.28)
DAS28(CRP), mean (SD) 5.2 (1.3) 5.5 (1.6) 5.3 (1.2) 5.6 (1.8)
Number of tender joints, mean (SD) 10.9 (7.4) 13 (10.1) 13.6 (8.6) 18.4 (10.1)
Number of swollen joints, mean (SD) 10.1 (5.4) 12.5 (8.7) 11.3 (5.6) 16.3 (8.6)
CRP (mg/L), median (quartiles) 8.4 (4.2-25.3) 14.0 (3.5-37.2) 6.9 (1.7-14.6) 3.7 (0.7 - 11.4)
Patients with positive rheumatoid factora,
number (%)
6 (75.0) 6 (60.0) 16 (88.9) 6 (66.7)
In this instance, the 10MCP Trans PDA for Panel A used data from all three baseline scans. There were no statistically significant differences, P >0.05, between
groups based on nonparametric Wilcoxon and t-tests. aPositive rheumatoid factor was defined as rheumatoid factor >= 12 KU/L, the reference range for Quest
assay. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; MCP, metacarpophalangeal joint; PDA; Power Doppler Area; SD, standard deviation.
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Figure 2 Within-panel comparisons (panel A and B) of US and DAS28(CRP) endpoint responsiveness. Effect size and 90% CI are
presented. Power Doppler measures: PDA: Power Doppler Area; continuous measure of PD signal within the synovium; VASCi: Vascular Index (0
to 4 scale). Gray scale US measure of synovial swelling: STA: Synovial Thickness Area; area bounded by synovium; STi: Synovial Thickness Index (0
to 4 scale). * Significant effect: P <0.05. CI, confidence interval.
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In fact, the effect size for this endpoint was numerically
the largest at Day 15 and 8 (for both panels) and Day 2
(for Panel A); and was the only endpoint to demonstrate
a significant treatment effect at Day 2 in Panel A. At Day
2 in Panel B, the 10MCP Long STi (a semi-quantitative
rather than quantitative measure of longitudinal ST area)
was the only endpoint to demonstrate a significant treat-
ment effect. Another notable endpoint was the 10MCP
Trans VASCi which demonstrated significant effect sizes
in both Panels at Day 15 and 8 (largest effect size was
within Panel A, Day 15 = 1.38).
None of the imaging endpoints showed a statistically
significant difference between the treatment effects of
the two prednisone doses. However, there was concor-
dance in the rank ordering of effect sizes for US end-
points in keeping with the prednisone dose.
Reproducibility of summated 10MCP score US endpoints
The within-scan inter-reader, parallel scan intra-reader
and parallel scan inter-reader reliability were good to
excellent for the majority of US measures. Overall mean
ICC values for within-scan inter-reader, parallel scan
intra-reader, and parallel scan inter-reader reliability
were 0.77, 0.83 and 0.61, respectively. Overall mean ICC
value for all quantitative measures of synovitis was
greater than for all semi-quantitative measures, 0.77 and
0.70, respectively (P = 0.77). The overall mean ICC
value for all longitudinal measures of synovitis was
greater than for all transverse measures, 0.80 and 0.68,
respectively (P = 0.16). The overall mean ICC value for
all power Doppler measures of synovitis was greater
than for all gray-scale measures, 0.84 and 0.63, respec-
tively (P = 0.002). P-values were computed assuming
independence of the ICC values via Wilcoxon Rank
Sum test, and are two-sided.
The endpoints with the best agreement at baseline or
on treatment were the VASCi (Long and Trans), both of
which are semi-quantitative measures of vascularity but
assessed in different planes (Table 3).
Panel A correlations between US endpoints and DAS28
(CRP)
Correlations assessed at baseline between US endpoints
and DAS28(CRP) were moderate and ranged between
0.52 and 0.68; all were statistically significant (P < 0.05).
At Days 15, 8 and 2, 96% of the correlations in the pla-
cebo group were between 0.5 and 0.9 (actual range 0.23
to 0.9) and 92% of the correlations were between 0.4
and 0.8 (actual range 0.11 to 0.80) in the prednisone
group.
Exploratory composite endpoint responsiveness
Each composite endpoint is a simple sum of the stan-
dardized score corresponding to the DAS28(CRP) and
two US endpoints, each summed across 10 MCPJs.
Effect sizes at Days 15, 8 and 2 for composite endpoints
constructed using the DAS28(CRP), Trans PDA/VASCi,
and Long STA/STi in Panel A are shown in Table 4.
These were selected as they generally had the largest
effect sizes at the three post-treatment time points. All
four composite endpoints demonstrated statistical signif-
icance after only a single day of dosing, that is, at Day 2.
The effect of prednisone 7.5 mg, Panel B, on the rela-
tively easy-to-score pre-defined composite endpoint
taken from the analysis of Panel A, Z-score(DAS28 +
Trans VASCi + Long STi), was significant at Days 15
and Day 8 (effect sizes 1.84 and 1.80, respectively).
Discussion
We have demonstrated that a wide range of HFUS mea-
sures of ST and PDUS measures of synovial vascularity at
the MCPJs are reproducible and capable of detecting
treatment effects of oral prednisone (15 mg and 7.5mg
daily) after a week, and two US measures after only one
day, in small panels of subjects (n = 18 and n = 27,
respectively) with moderate to severely active RA. DAS28
(CRP) was only able to detect a significant treatment
effect after two weeks in the 15 mg cohort. US may,
therefore, be a leading indicator of therapy response
occurring before a clinical response. At present, more
than 50% of drugs tested fail at phase III and the expense
of the traditional drug development pathway has become
prohibitive for numerous novel compounds developed to
selectively inhibit a range of potential therapeutic targets
that have been identified for RA. Our study has exten-
sively investigated the sensitivity and reliability of a
diverse range of two-dimensional ultrasonographic end-
points at the MCPJ and their potential as tools to provide
an early and objective indication of a therapeutic
response to treatment intervention in RA. We have con-
firmed that ultrasonography of MCPJ is an early, reliable
indicator of therapeutic response in RA and it thus has
the potential to reduce patient numbers required as well
as the duration of clinical trials designed to give a preli-
minary indication of efficacy. Such an approach to early
drug development in RA might increase the chances of
success in later phase studies designed to meet the regu-
latory endpoints that are required to achieve approval.
In the present study, correlations between the majority
of different US endpoints and DAS28(CRP) while on pre-
dnisone treatment were between 0.4 and 0.8, suggesting
that they measure somewhat different constructs.
Combining US endpoints with DAS28(CRP) increased
effect sizes at all time points and identified treatment
effects earlier. Composite endpoints increased the end-
point sensitivity for 15 mg in Panel A. The DAS28(CRP)
had an effect size of about 1.0, which would take 13 sub-
jects per group to identify a treatment difference (alpha
Seymour et al. Arthritis Research & Therapy 2012, 14:R198
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0.1; 80% power). In combination with a US endpoint with
combined effect size of approximately 1.5, the sample
number drops to six per group. Some combinations of
US endpoints with effect sizes of approximately 2.0
would require four subjects per group. Likewise, single
dose effects of 15 mg prednisone were identifiable with
some combinations of endpoints. These findings strongly
suggest a potential value in employing such composite
endpoints in future prospective small studies designed to
establish an early indication of efficacy. Composite end-
points were selected from Panel A on how well they per-
formed. They were tested in Panel B in a predefined way
but in a limited capacity. These composite endpoints
need to be tested in future studies to confirm their utility.
Both 15 mg and 7.5 mg prednisone represent rela-
tively low corticosteroid doses and it would be notable if
an endpoint could differentiate their effect. Overall,
there was a trend towards a dose-response. Greater
Table 3 Reproducibility of US endpoints.
10 MCP US endpoint Reproducibility method Baseline ICC (95% CI) Day 15 ICC (95% CI)
Long PDA Within-scan inter-reader 0.89 (0.80; 0.99) 0.98 (0.95; 1.00)
Parallel scan intra-reader 0.80 (0.64; 0.96) 0.62 (0.36; 0.88)
Parallel scan inter-reader 0.78 (0.59; 0.97) 0.68 (0.45; 0.92)
Long STA Within-scan inter-reader 0.76(0.56; 0.95) 0.81 (0.65; 0.97)
Parallel scan intra-reader 0.95 (0.90; 1.00) 0.83 0.68; 0.98)
Parallel scan inter-reader 0.85 (0.72; 0.98) 0.71 (0.48; 0.95)
Long STi Within-scan inter-reader 0.67 (0.40; 0.93) 0.54 (0.20; 0.88)
Parallel scan intra-reader 0.87 (0.75; 0.99) 0.82 (0.66; 0.98)
Parallel scan inter-reader 0.67 (0.42; 0.93) 0.46 (0.07; 0.85)
Long VASCi Within-scan inter-reader 0.90 (0.81; 0.99) 0.94 (0.88; 1.00)
Parallel scan intra-reader 0.93 (0.87; 0.99) 0.94 (0.88; 1.00)
Parallel scan inter-reader 0.83 (0.67; 0.98) 0.85 (0.72; 0.99)
Trans PDA Within-scan inter-reader 0.99 (0.98; 1.00) 1.00 (0.99; 1.00)
Parallel scan intra-reader 0.75 (0.57; 0.93) 0.76 (0.57; 0.94)
Parallel scan inter-reader 0.72 (0.51; 0.93) 0.75 (0.55; 0.96)
Trans STA Within-scan inter-reader 0.52 (0.33; 0.72) 0.57 (0.36; 0.79)
Parallel scan intra-reader 0.83 (0.68; 0.98) 0.92 (0.85; 0.99)
Parallel scan inter-reader 0.57 (0.24; 0.89) 0.40 (0.01; 0.80)
Trans STi Within-scan inter-reader 0.48 (0.19; 0.76) 0.36 (0.10; 0.62)
Parallel scan intra-reader 0.83 (0.68; 0.98) 0.77 (0.58; 0.97)
Parallel scan inter-reader 0.00 (-0.46; 0.46) 0.01 (-0.46; 0.48)
Trans VASCi Within-scan inter-reader 0.92 (0.84; 0.99) 0.96 (0.92; 1.00)
Parallel scan intra-reader 0.73 (0.52; 0.94) 0.91 (0.84; 0.99)
Parallel scan inter-reader 0.68 (0.45; 0.92) 0.78 (0.60; 0.96)
ICC (intraclass correlation coefficient) values of <0.40, poor to fair agreement; 0.41 to 0.60, moderate agreement; 0.61 to 0.80, good agreement; and 0.81 to 1.00,
excellent agreement. CI, confidence interval; PDA; Power Doppler Area; STA, synovial thickness area; STi, synovial thickness index; VASCi, vascularity index.
Table 4 Performance of exploratory composite endpoints.
Endpoint Scan Day 15 Effect size (90% CI) Day 8 Effect size (90% CI) Day 2 Effect size (90% CI)
Z-score(DAS28+Trans VASCi+Long STi) 1 1.96 (0.97; 2.90) 1.41 (0.46; 2.32)) 1.28 (0.40; 2.13)
Z-score(DAS28+Trans VASCi+Long STA) 1 2.05 (1.05; 3.01) 1.53 (0.56; 2.46) 1.14 (0.28; 1.98)
Z-score(DAS28+TransPDA +Long STA) 1 2.14 (1.12; 3.10) 1.17 (0.25; 2.05) 1.14 (0.28; 1.98)
Z-score(DAS28+TransPDA +Long STi) 1 1.93 (0.95; 2.87) 0.98 (0.09; 1.84) 0.95 (0.11; 1.76)
DAS28(CRP) 0.95 (0.11; 1.76) 0.75 (-0.12; 1.59) 0.67 (-0.15; 1.46)
Panel A (Prednisone 15mg versus Placebo) effect sizes for composite endpoints at Day 15, Day 8 and Day 2 compared with DAS28(CRP). The sum of the
standardized score of DAS28(CRP), 10 MCP Trans VASCi, 10MCP Long STi (Z-score(DAS28+Trans VASCi+Long STi)); the sum of the standardized score of DAS28
(CRP), 10 MCP Trans VASCi, 10 MCP Long STA (Z-score(DAS28+Trans VASCi+Long STA)); the sum of the standardized score of DAS28(CRP), 10 MCP Trans PDA,
10 MCP Long STA (Z-score(DAS28+Trans PDA+Long STA)); and the sum of the standardized score of DAS28(CRP), 10 MCP Trans PDA, 10 MCP Long STi (Z-score
(DAS28+Trans PDA +Long STi)). Note: If the 90% confidence interval excludes zero (or values less than zero) then the value is significant at the <0.05 level for a
one-sided comparison. We have prior information giving us the directionality of change and are only interested in change in one direction. Therefore, all the
above effect sizes for composite endpoints were significant at all post dose time points and for DAS28(CRP) at Day 15 only. CI, confidence interval; CRP,
C-reactive protein; DAS28, Disease Activity Score in 28 Joints; PDA; Power Doppler Area; STA, synovial thickness area; STi, synovial thickness index; VASCi,
vascularity index.
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numbers of subjects may have discriminated the two
doses. Other factors that may have decreased the study’s
ability to differentiate the two doses include the fact
that there were two centers, the scanning rooms of
which, for example, may have been at different tempera-
tures, and there were two ultrasonographers, the first
scans of each in their respective centers were used to
determine treatment effect.
For Panel B the 10MCP Trans PDA demonstrated a
significant treatment effect earlier than in Panel A. This
may be because there were more subjects in Panel B
who received active treatment, albeit at a lower dose. To
support this, at Day 8 more US endpoints registered a
significant treatment effect for Panel B than Panel A.
For Panel A, seven out of eight US endpoints demon-
strated a consistent time-response to 15mg of predni-
sone. Within Panel B more US endpoints registered a
significant effect size at Day 8 in comparison with Day 15
perhaps due to waning of therapeutic response to low
dose corticosteroid in some subjects. The observed tran-
sient response of the US endpoints to 7.5 mg of predni-
sone was mirrored in the effect sizes of the DAS28(CRP)
even though this latter endpoint did not show signifi-
cance at any time point. We postulate that for some sub-
jects in Panel B, 7.5mg of prednisone may be just below
the threshold dose for a sustained anti-inflammatory
effect. The biological response to prednisone at low
doses (≤7.5 mg/day prednisone or equivalent), is not
necessarily predictable in inducing and sustaining an
anti-inflammatory effect in RA [29]. If we had used larger
doses of prednisone in the study, for example 40mg, we
would have undoubtedly seen more consistent time-
responses but this would have weakened the impact of
the study as it would not have permitted a demonstration
of the sensitivity of US to detect change.
The Long STA endpoint performed especially well in the
current study. Our previous investigations of HFUS gray-
scale ST have shown inferiority to power Doppler vascular-
ity in detecting a treatment effect with respect to the
kinetics and the extent of change [27,30]. However, those
studies measured synovial thickening semi-quantitatively in
the transverse plane only. Semi-quantitative indices may
constrain the detection of change in joints if synovial thick-
ening greatly exceeds the largest score by delivering static
scores when genuine reduction in synovial thickening can
be detected quantitatively. The greater area afforded by the
longitudinal versus the transverse view may have also bene-
fited the registration of a treatment effect by the Long STA
endpoint. The data in the current study support these the-
ories: semi-quantitative measures of synovial thickening
had smaller effect sizes than quantitative measures (the
only exception was Day 2, panel B); transverse measures of
synovial thickening had smaller effect sizes than longitudi-
nal measures (the only exception was Day 2, Panel A;
Figure 2). The treatment effect was less at Day 2 and,
therefore, these factors would have had less influence at
this early time point.
Most US studies have investigated reliability on a joint
by joint basis. Few have assessed reliability of a summa-
tion of scores for a selected group of joints. Naredo et al.
assessed within scan intra-reader reliability with a resul-
tant excellent ICC value of 0.99 [10] for summated
4-point semi-quantitative PDUS imaging of 28 joints,
called the ‘overall US joint index for power Doppler sig-
nal’. Backhaus et al. [31] developed a composite US score
called the ‘German US7 score’. They measured HFUS
synovitis and PD synovitis using 4-point semi-quantita-
tive scales in seven joints and the within scan inter-reader
reliability kappa value was 0.6. Arguably the most robust
measure of reliability is the ‘parallel scan inter-reader’
(included in our study) because it is a comparison
between two ultrasonographer-readers scanning the
same patient. The images are read independently, as
might be the case in multi-site clinical trials using the
same model of US machine and settings. As expected the
overall reproducibility for parallel scan inter-reader relia-
bility was lower than within scan inter-reader reliability;
the difference between these two methods most likely
representing the loss of concordance due to image acqui-
sition. A similar observation was reported by Kamishima
et al. [32]. Despite this shortfall, in the current study
good agreement was observed for the overall parallel
scan inter-reader reliability. The overall parallel scan
intra-reader reliability was strongest demonstrating the
potential advantage of one ultrasonographer acquiring
and reading the scans at a single site.
Quantitative ultrasonographic measures of synovitis
demonstrated better overall reliability than semi-quanti-
tative measures although the difference was not statisti-
cally significant. Therefore, within future studies there
may still be a place for more time-consuming measures
of synovitis, by computationally quantifying pixel counts,
but quicker semi-quantitative scales may be an accepta-
ble substitute. We observed that power Doppler mea-
sures of synovitis were significantly more reproducible
than gray-scale measures of synovitis and we advocate
that future US studies include power Doppler vascularity
endpoints to deliver optimum reliability.
The dimensions of the transducers available for use in
this study may have been a limitation resulting in weak
inter-reader reliability (within-scan or parallel scan) for
the 10MCP Trans STi and the 10MCP Trans STA.
Because of the broad width of the transducer relative to
the deepest point of the triangular structure (which is a
narrow precise location), more than one hyperechoic
line, representing bone, is often observed on the saved
gray-scale image. Therefore, MS and SK may have cho-
sen different ROIs depending on which line was selected
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to represent the lower border of the triangular structure,
even though, from the beginning of the study, there was
a consensus to use the lowest hyperechoic line.
Another limitation of our study is that the two predni-
sone doses were trialed in series rather than in parallel
and, therefore, although comparisons can be made
between treatment groups, firm conclusions are ham-
pered. This is especially relevant when attempting to
comment on the dose-response of the US endpoints to
prednisone.
Due to the time constraints of scanning we restricted
our US evaluation to the dorsum of the MCPJs. It may
have been valuable to have assessed endpoints derived
from imaging over the palmar surface also.
Conclusions
Our study confirms that ultrasonographic imaging of
MCPJs could be used as an early and reliable indicator
of a therapeutic response to a new treatment interven-
tion in RA early phase clinical trials with small patient
cohorts over a two-week test period and decrease the
time-to-decision for progressing clinical development.
By addressing the issues surrounding the reliability of
US to measure synovitis objectively this study brings us
closer to approving this tool as a recognized endpoint
for confirming treatment effect in RA clinical trials. The
semi-quantitative US endpoints demonstrated in this
study, whether used alone or together with clinical mea-
sures as composite endpoints, could be used in centers
not possessing quantitative analysis tools. The study also
illustrates the potential utility of US to stratify patient
selection by detecting those with potentially reversible
baseline joint inflammation, an important consideration
given concerns about bias introduced in trials by
recruitment of patients with equivocal clinical swelling.
Moreover, composite endpoints have the potential to
further reduce patient numbers and study duration in
early phase trials.
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